Stock listing

Stockholm:PROGEN Prostatype Genomics AB Aktie

Home listing (Stockholm) of Prostatype Genomics AB

Follow Prostatype Genomics AB into a list and get an email when it puts out news.

Share price · OMXSTO:PROGEN

0.108 SEK +0.001 (+0.5%)

Close on Oct 30, 2026

Past year -82.6% · daily closes, Oct 30, 2025 – Oct 30, 2026, adjusted for splits
Day range
0.100 – 0.108 SEKOct 30, 2026
Volume
1.39M sharesOct 30, 2026
Market cap
16.72M SEKAt the close on Oct 30, 2026 · price × 155.6M shares outstanding
52-week range
0.079 – 2.280 SEKLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
Traded on an average day
1.03M SEKMedian day 5.90M shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prostatype Genomics AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:PROGEN · Home0.108 SEK+0.001 (+0.5%)1,388,2040.1070.1080.1000.107Close on Oct 30, 2026
Frankfurt:PGO0€0.0050 EUR-0.0018 (-26.5%)—€0.0048€0.0072€0.0048€0.0068Close on Oct 30, 2026

Daily closes

Last 3 months, Jul 30, 2026 – Oct 30, 2026 · OMXSTO:PROGEN · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
0.108+0.001+0.5%0.1070.1080.1001,388,204
0.1070.0000.0%0.1070.1120.1041,885,689
0.107+0.008+8.3%0.1040.1080.0972,597,708
0.099-0.002-2.2%0.1010.1040.0961,904,194
0.101-0.001-1.0%0.1010.1010.0914,928,286
0.102+0.006+6.2%0.0970.1050.0972,586,003
0.096-0.007-6.8%0.1030.1050.0962,104,575
0.103+0.001+1.0%0.0990.1050.0991,853,618
0.102+0.002+2.0%0.1000.1050.0953,882,475
0.100-0.004-3.8%0.1040.1050.0947,710,108
0.104-0.002-1.9%0.1100.1130.1023,010,539
0.106-0.009-7.4%0.1150.1180.1065,137,524
0.115+0.009+8.0%0.1050.1170.10011,548,477
0.106+0.001+0.5%0.1060.1090.0994,276,538
0.106+0.014+14.9%0.0920.1100.09213,201,840
0.092+0.005+6.3%0.0870.0930.0875,783,654
0.086-0.001-0.7%0.0870.0910.0835,658,802
0.087+0.001+1.2%0.0880.0880.07913,242,138
0.086-0.006-6.5%0.0910.0920.08611,239,079
0.092-0.002-2.5%0.0940.0940.0904,570,119
0.094+0.001+1.3%0.0910.0990.0889,136,840
0.093-0.004-3.9%0.0970.0990.09011,953,299
0.097+0.000+0.4%0.0970.1120.09520,499,473
0.097-0.008-7.6%0.1060.1070.09521,156,567
0.105-0.018-14.3%0.1220.1220.09418,399,426
0.122+0.006+5.6%0.1150.1240.1145,196,575
0.116-0.004-3.7%0.1220.1370.1138,449,379
0.120-0.023-16.1%0.1430.1480.11216,351,552
0.143-0.004-2.7%0.1470.1490.1365,903,132
0.147-0.009-5.8%0.1590.1610.1427,278,147
0.156-0.005-2.8%0.1610.1650.1532,117,241
0.161-0.005-2.7%0.1660.1700.1586,025,525
0.165+0.006+3.8%0.1590.1650.1572,619,833
0.159+0.003+1.9%0.1560.1610.1483,815,993
0.156-0.003-1.9%0.1600.1600.1532,995,014
0.159-0.011-6.5%0.1700.1700.1528,565,761
0.1700.0000.0%0.1730.1730.1597,368,268
0.170-0.005-2.9%0.1760.1810.15914,439,042
0.175+0.023+15.1%0.1520.1750.1528,600,388
0.152+0.005+3.4%0.1470.1530.1443,597,796
0.147+0.001+0.3%0.1470.1540.1434,023,053
0.147-0.001-0.3%0.1480.1570.1435,063,148
0.147+0.005+3.2%0.1430.1600.1436,713,060
0.143+0.003+2.5%0.1460.1600.13110,474,154
0.139-0.010-7.0%0.1500.1660.13714,639,284
0.150-0.009-5.4%0.1590.1630.1406,684,759
0.158-0.014-7.9%0.1730.1730.15215,178,822
0.172+0.016+9.9%0.1600.1800.15720,106,874
0.1560.0000.0%0.1610.1720.14031,159,252
0.156+0.030+23.3%0.1310.1600.13038,207,457
0.127+0.011+10.0%0.1180.1310.11719,077,580
0.115+0.008+7.0%0.1090.1200.1098,283,150
0.108+0.004+3.4%0.1050.1080.1013,478,433
0.104+0.002+2.0%0.1030.1090.1005,509,835
0.102+0.004+4.1%0.0980.1050.09717,368,074
0.098+0.001+1.0%0.0970.0980.0936,926,800
0.097-0.001-1.4%0.0980.1040.09110,913,288
0.098-0.002-2.1%0.1030.1080.0986,611,105
0.101-0.004-3.8%0.1050.1050.0995,429,084
0.105-0.045-30.1%0.1050.1080.09414,718,165
0.150+0.005+3.5%0.1450.1600.145436,769
0.145-0.033-18.4%0.1790.1850.1391,501,973
0.177-0.003-1.7%0.1750.1890.165139,020
0.180+0.001+0.3%0.1800.2100.1781,263,029
0.180+0.019+12.2%0.1650.2020.1651,244,856
0.160+0.004+2.6%0.1430.1620.1421,140,806
0.156-0.008-4.6%0.1540.1650.145362,608
Ticker
Stockholm:PROGEN
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Stockholm
Currency
SEK

What changed lately

Latest news

Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6

Sep 17, 2026

Closed 0.156 (-2.8%) on Sep 18, 2026

Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6

Aug 31, 2026

Closed 0.139 (-7.0%) on Aug 31, 2026

Prostatype Genomics AB resolves on a directed issue

Aug 5, 2026

Closed 0.145 (-18.4%) on Aug 6, 2026

Prostatype Genomics AB announces last day of trading in BTUs and first day of trading in warrants of series TO6 and TO7

Aug 3, 2026

Closed 0.18 (+0.3%) on Aug 4, 2026

Prostatype Genomics AB announces outcome in rights issue of units

Jul 27, 2026

Closed 0.157 (-1.9%) on Jul 28, 2026

Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026

Jul 21, 2026

Closed 0.155 (-13.9%) on Jul 21, 2026

The subscription period in Prostatype Genomics AB's rights issue of units begins today

Jul 9, 2026

Closed 0.20 (-11.1%) on Jul 9, 2026

Prostatype Genomics AB publishes information memorandum prior to rights issue of units

Jul 8, 2026

Closed 0.20 (-11.1%) on Jul 9, 2026

Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units

Jul 8, 2026

Closed 0.20 (-11.1%) on Jul 9, 2026

Prostatype Genomics provides financing update

Jun 30, 2026

Closed 0.151 (-7.7%) on Jul 1, 2026

All Prostatype Genomics AB news

Financings

  • New shares through exercise of warrants of series TO6

    Sep 17, 2026 · US$1.27M

    Closed: SEK 12.5M raised · SEK 0.1 a share · Vator Securities AB +2

    Dealers: Vator Securities AB, Navia Corporate Finance AB, Birchtree Advisory AB

    Buyers: Vator Securities AB (8,156,289 shares at SEK 0.10 in the Directed Share Issue (underwriting and compensation shares))

    Insiders: Letters of intent from the Board of Directors, management and other warrant holders corresponding to approximately SEK 2.27 million

    Use of proceeds: Liquidity and financial position of the company

    Announced Aug 31, 2026 · Closed Sep 17, 2026

  • Rights offering of units (shares and warrants of series TO6 and TO7)

    Aug 3, 2026 · US$4.88M

    Closed: SEK 47.4M raised · SEK 0.1 a unit · Warrants at SEK 0.1 · Navia Corporate Finance AB +2

    Dealers: Navia Corporate Finance AB (co-lead), Birchtree Advisory AB (co-lead), Vator Securities AB

    Insiders: Subscription commitments from existing major shareholders, including members of the Board of Directors, totalling approximately SEK 9.2 million

    Use of proceeds: Accelerate commercialization of Prostatype, strengthen presence in prioritized markets and continue company development

    Update Jul 8, 2026 · Update Jul 9, 2026 · Update Jul 21, 2026 · Closed Jul 27, 2026 · Update Aug 3, 2026

Read by 6ix AI from the company's releases

Prostatype Genomics AB on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
15 in the last 12 months · 21 in all · newest Sep 17, 2026 · oldest 2025

Where Prostatype Genomics AB is listed

ListingExchangeCountryCurrency
Stockholm:PROGEN · Home listing · This pageStockholmSwedenSEK
OTC:PGABFOTCUnited StatesUSD
Frankfurt:PGO0FrankfurtGermanyEUR

Log in to ask 6ix AI your own questions about Prostatype Genomics AB.